Alps Advisors Inc Akebia Therapeutics, Inc. Transaction History

Alps Advisors Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 07, 2019	SELL	$4.1 - $8.05 $1.16 Million - $2.27 Million	-282,329 Closed	0 $0
Q1 2019 May 01, 2019	BUY	$5.41 - $8.73 $335,062 - $540,683	61,934 Added 28.1%	282,329 $2.31 Million
Q4 2018 Feb 04, 2019	BUY	$5.39 - $9.15 $643,819 - $1.09 Million	119,447 Added 118.33%	220,395 $1.22 Million
Q3 2018 Oct 25, 2018	BUY	$7.44 - $10.65 $136,888 - $195,949	18,399 Added 22.29%	100,948 $891,000
Q2 2018 Aug 02, 2018	BUY	$9.15 - $11.34 $276,055 - $342,127	30,170 Added 57.6%	82,549 $824,000
Q2 2018 Jul 25, 2018	SELL	$9.15 - $11.34 $100,823 - $124,955	-11,019 Reduced 17.38%	52,379 $779,000
Q1 2018 May 01, 2018	BUY	$9.53 - $15.68 $105,011 - $172,777	11,019 Added 21.04%	63,398 $604,000
Q4 2017 Feb 05, 2018	BUY	$14.24 - $19.59 $85,539 - $117,677	6,007 Added 12.95%	52,379 $779,000
Q3 2017 Nov 03, 2017	BUY	$13.06 - $19.67 $605,618 - $912,137	46,372	46,372 $912,000

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.